Cure8 research brief
UGI involvement in children with IBD was common and linked to a more severe disease course — lower remission rates and more frequent need for biologic therapy — which could affect monitoring and treatment planning.
Pediatric IBD patients and their caregivers; pediatric gastroenterologists; researchers focused on pediatric IBD severity and treatment escalation.
This retrospective cohort study of children diagnosed with IBD who had upper gastrointestinal (UGI) endoscopic evaluation at diagnosis found UGI involvement in 68% of patients (higher in Crohn’s than ulcerative colitis).
UGI involvement was linked with lower chances of achieving clinical and biomarker remission and with a higher likelihood of starting biologic therapy during follow-up.
The paper suggests that examining the UGI tract at diagnosis can provide prognostic information: children with UGI disease tended to have a more severe course and were more likely to escalate to biologic treatment.
These findings do not prescribe specific treatments but support using early upper endoscopy as part of initial evaluation to help guide monitoring and management decisions alongside other clinical factors.
Retrospective cohort data show associations but cannot prove causality. Review full methods (remission definitions, follow-up length, adjustment for confounders) before changing practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If validated, an early drop in fecal calprotectin could help identify patients on biologic therapy who are likely to achieve mucosal healing without waiting for invasive endoscopy, allowing earlier decisions about...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
